Myriad Genetics Q2 2026 revenue fell 11% to $190.7 million; net loss narrowed to $43.2 million, or $0.46 per share.
Gross margin dropped 4.6 percentage points to 66.6%; operating loss narrowed to $38.9 million.
Test volumes slipped 1% to 379,000; average revenue per test fell 9%, partly reflecting an $11 million revenue reduction tied to cash-collection estimates.
Segment performance
Cancer Care Continuum volumes rose 6% to 95,000 while revenue fell 11% to $114.1 million.
Prenatal Health volumes fell 9% to 144,000.
Updated outlook and efficiency initiative
Myriad revised its FY 2026 revenue outlook to $770 million-$790 million.
The company suspended adjusted EBITDA guidance while launching the Ascend efficiency initiative.
MYGN•
